Samsung Bioepis Expands Ophthalmology Portfolio with European Launch of OPUVIZ
INCHEON, South Korea, May 29, 2026 Samsung Bioepis Co., Ltd. has announced the European launch of OPUVIZ™ (aflibercept) 40...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
INCHEON, South Korea, May 29, 2026 Samsung Bioepis Co., Ltd. has announced the European launch of OPUVIZ™ (aflibercept) 40...
AMSTERDAM, Netherlands and BURBANK, Calif., May 28, 2026 Royal Philips and The Walt Disney Company have announced a groundbreaking...
